FDA grants Priority Review to Dupixent® for kids 6 months to 5 years
February 10th 2022The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.
Available biologics for treating asthma and allergic skin disease
October 11th 2021In cases of poorly controlled disease, even with good medication adherence, it might make sense to turn to biologics. A presentation at the virtual 2021 American Academy of Pediatrics National Conference & Exhibition covered biologics available for treating asthma and allergic skin disease.
Pearls for treating dermatologic conditions in skin of color
October 9th 2021Treating dermatologic conditions in skin of color requires cultural awareness and sensitivity, in addition to being aware of how presentation may differ. At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, a session offered clinical pearls.